The three-year research collaboration utilizes Vernalis' strengths in structure and biophysics-based methods and Servier's oncology expertise to research new cancer therapeutic targets based on previously undisclosed proteins. A prior collaboration led to the discovery of several compounds that are currently in clinical trials, including Bcl-2 and Mcl-1.

Vernalis will leverage its Vernalis design platform, which integrates protein structure determination, protein engineering, fragment screening, and molecular modeling with medicinal chemistry to successfully develop novel drug candidates against highly challenging oncology targets.

Vernalis will receive research and success fees, as well as milestone payments and royalties on sales if Servier advances any identified targets. Financial terms of the agreement were not disclosed.

Ligand, Roche to develop ion channel drug discovery platform
Ligand Pharmaceuticals and Icagen have expanded Icagen's license agreement with Roche to develop and commercialize small molecule ion channel modulators...